Stock TH THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Theratechnologies Inc.

Equities

TH

CA88338H7040

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.81 CAD +0.56% Intraday chart for Theratechnologies Inc. -10.84% -15.42%
Apr. 10 Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision MT
Apr. 10 Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
AQ
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
AQ
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision
MT
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug
MT
Transcript : Theratechnologies Inc., Q1 2024 Earnings Call, Apr 10, 2024
Theratechnologies: Fiscal Q1 Earnings Snapshot
AQ
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024
CI
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level
MT
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million
MT
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA
MT
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
AQ
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024
CI
North American Morning Briefing : Traders Await -2-
DJ
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
AQ
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform
CI
Theratechnologies Appoints Elina Tea to its Board of Directors
AQ
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee
CI
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
AQ
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform
MT
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TH Stock
  4. News Theratechnologies Inc.